FluiDx-AD is a collaborative project aimed at improving Alzheimer’s disease (AD) diagnosis and management through the development of innovative saliva and blood-based diagnostic tests. These tests will improve early detec-tion, facilitate access to next-generation treatments and to enhance the quality of life for millions affected by AD. On 26 November, three members of the FluiDx-AD advisory board met with Faye Forsyth and Christophe Bintener (Alz-heimer Europe) for the first online meeting. The main topics of discussion were project related documents, which the group reviewed, and the benefits and drawbacks of poten-tially diagnosing AD via a test that can be done at home. Fruitful discussions were held about potential ethical issues, and multiple insightful comments that have greatly improved the project documents were made. FluiDx-AD is co-funded by the European Union. Further information can be found on the project’s website: https://www.fluidx-ad.eu/
